AstraZeneca and Daiichi Sankyo have reported positive Phase 3 clinical trial results for Datroway (their novel antibody-drug conjugate) in treatment of hard-to-treat triple-negative breast cancer (TNBC). The success signals a potential new therapeutic option that may replace traditional chemotherapy in selected TNBC patient populations. Datroway has previously obtained approvals in other breast and lung cancers, and the new data could expand its label indications. This development could mark significant progress in immunotherapy-based targeted cancer treatments for aggressive malignancies.